Pyxis Oncology, Inc. SEC filings PYXS

Pyxis Oncology, Inc. has 356 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Oct 21, 2026 Oct 21, 2026
PRE 14A Preliminary proxy statement Oct 9, 2026 Oct 9, 2026
DEFA14A Additional proxy material Apr 30, 2026 —
DEF 14A Proxy statement Apr 30, 2026 Apr 30, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Apr 29, 2025
DEF 14A Proxy statement Sep 25, 2024 Sep 25, 2024
PRE 14A Preliminary proxy statement Sep 13, 2024 Sep 13, 2024
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 11, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 13, 2023
DEFA14A Additional proxy material Apr 28, 2022 —
DEF 14A Proxy statement Apr 28, 2022 Jun 13, 2022

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PYXS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1782223

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.